Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18948050 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | November 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18923620 | ANTI-AGING PREPARATION FOR SKIN AND APPLICATION THEREOF | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18669214 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS | May 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18668526 | METHOD TO SELECTIVELY PRODUCE BENZALANILINE FROM A SCHIFF-BASE REACTION INVOLVING ANILINE AND BENZALDEHYDE | May 2024 | February 2025 | Allow | 9 | 2 | 0 | No | No |
| 18648426 | TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB | April 2024 | March 2025 | Allow | 10 | 2 | 0 | No | No |
| 18647511 | METHODS AND COMPOSITIONS FOR TREATING CANCER | April 2024 | April 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18637083 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18624670 | TREATMENTS WITH NIROGACESTAT | April 2024 | October 2024 | Allow | 6 | 2 | 0 | No | No |
| 18618110 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | March 2024 | February 2025 | Allow | 11 | 2 | 1 | No | No |
| 18581307 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | February 2024 | April 2025 | Allow | 14 | 1 | 1 | No | No |
| 18439677 | FABRICATION OF NOVEL NANO-SIZED [4{3,4-BIS-[(5-BROMO-2-HYDROXY-BENZYLIDENE)-AMINO]-PHENYL}-PHENYL-METHANONE] RU(III) COMPLEX FOR PHARMACEUTICAL APPLICATIONS | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18417750 | COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND | January 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18414185 | TREATMENTS WITH NIROGACESTAT | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18538562 | METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18386906 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | November 2023 | March 2025 | Allow | 16 | 2 | 0 | No | No |
| 18498542 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | October 2023 | January 2025 | Allow | 15 | 2 | 0 | No | No |
| 18470182 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE ASSOCIATED INFLAMMATION AND DISORDERS | September 2023 | November 2024 | Allow | 14 | 2 | 0 | No | No |
| 18460047 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | September 2023 | December 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18238905 | Series of Skin-Whitening (Lightening) Compounds | August 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18237140 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | August 2023 | August 2024 | Allow | 12 | 1 | 0 | No | No |
| 18362789 | CATIONIC LIPIDS AND TRANSFECTION METHODS | July 2023 | April 2025 | Allow | 21 | 2 | 0 | No | No |
| 18358998 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | July 2023 | June 2024 | Allow | 11 | 1 | 0 | No | No |
| 18215257 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | June 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18315404 | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DION | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18315041 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | May 2023 | October 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18314442 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18297974 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | April 2023 | February 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18297134 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | April 2023 | October 2024 | Allow | 19 | 2 | 0 | No | No |
| 18188706 | METHOD FOR TREATING CANCER | March 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18124959 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER | March 2023 | April 2025 | Allow | 25 | 1 | 0 | No | No |
| 18117075 | METHODS OF TREATING CANCER WITH AN FGFR INHIBITOR | March 2023 | May 2024 | Allow | 15 | 2 | 0 | No | No |
| 18067975 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | December 2022 | March 2025 | Allow | 27 | 0 | 1 | No | No |
| 18057724 | ANTIBACTERIAL HYDROPHILIC COMPOUND | November 2022 | June 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17778298 | CARBALYSOPHOSPHATIDIC ACID | November 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17937599 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | October 2022 | March 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17995002 | CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERS | September 2022 | May 2025 | Allow | 32 | 0 | 0 | No | No |
| 17946101 | Benzisoxazole Sulfonamide Derivatives | September 2022 | February 2024 | Allow | 17 | 1 | 0 | No | No |
| 17887480 | Series of Compounds for Treatment of Skin Diseases and Other Conditions | August 2022 | March 2025 | Allow | 31 | 2 | 1 | No | No |
| 17882905 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY | August 2022 | September 2024 | Allow | 26 | 2 | 0 | No | No |
| 17877485 | PARTICLE-FORM HYBRID-SCALE FIBER MATRIX | July 2022 | June 2023 | Abandon | 10 | 1 | 1 | No | No |
| 17751540 | BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF | May 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17750262 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF USING THE SAME | May 2022 | January 2024 | Allow | 20 | 2 | 0 | No | No |
| 17770515 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING CANCER USING PYRVINIUM COMPOSITIONS | April 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17714268 | SOLID STATE FORMS OF RELUGOLIX | April 2022 | June 2025 | Allow | 39 | 1 | 0 | No | No |
| 17695767 | CXCL10 Inhibitors | March 2022 | November 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17670078 | ALCOHOL-RESISTANT DRUG FORMULATIONS | February 2022 | June 2025 | Allow | 40 | 2 | 1 | No | No |
| 17630124 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | January 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17628017 | CARBAMATE-SUBSTITUTED STYRYL SULFONE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17568817 | SOLID STATE FORMS OF VALBENAZINE | January 2022 | September 2024 | Allow | 33 | 0 | 0 | No | No |
| 17562492 | KRAS mutant protein inhibitors | December 2021 | August 2024 | Allow | 32 | 1 | 1 | No | No |
| 17622389 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | December 2021 | March 2025 | Allow | 39 | 1 | 0 | No | No |
| 17618882 | MEDICAMENT AND USE THEREOF FOR TREATING BACTERIAL INFECTIONS INVOLVING BIOFILM | December 2021 | May 2025 | Allow | 41 | 2 | 0 | No | No |
| 17052078 | NOVEL CDK 8/19 INHIBITORS | December 2021 | April 2025 | Abandon | 53 | 0 | 1 | No | No |
| 17617716 | SYNERGISTIC CLEANING DISINFECTANT SOLUTION WITH ENHANCED STABILITY, AND METHODS OF USING THE SAME | December 2021 | October 2024 | Allow | 34 | 1 | 0 | No | No |
| 17596022 | QUINAZOLINE PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | December 2021 | March 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17595877 | USES OF DOXADIAZINES COMPOUNDS | November 2021 | April 2025 | Allow | 41 | 2 | 0 | No | No |
| 17595249 | PHENANTHRENE AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | November 2021 | March 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17599193 | Topoisomerase II-alpha Inhibitors and Methods of Treating Cancer Using the Same | September 2021 | February 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17593773 | SOLID FORM OF AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17438827 | SPECIFICALLY SUBSTITUTED 3-PHENYL-5-SPIROCYCLOPENTYL-3-PYRROLIN-2-ONES AND THEIR USE AS HERBICIDES | September 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17435824 | SOLID STATE FORMS OF BALOXAVIR MARBOXIL | September 2021 | October 2024 | Allow | 38 | 1 | 0 | No | No |
| 17431950 | HETEROCYCLIC COMPOUND AND HARMFUL ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME | August 2021 | November 2024 | Allow | 39 | 1 | 1 | No | No |
| 17395838 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | August 2021 | May 2024 | Allow | 33 | 1 | 1 | No | No |
| 17416977 | Cancer Treatment Useing Docetaxel by Controlling Peak Plasma Levels | June 2021 | March 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17295476 | SUBSTITUTED PYRIMIDINIUM COMPOUNDS FOR COMBATING ANIMAL PESTS | May 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17290353 | HALOGENATED SALICYLANILIDES FOR TREATING THE SYMPTOMS OF DERMATITIS | April 2021 | March 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17285261 | COMPOSITION CONTAINING MICROORGANISMS FOR PROMOTING GROWTH AND REDUCING HYDRIC STRESS IN CULTIVATED PLANTS AND USE THEREOF | April 2021 | November 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17168155 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | February 2021 | June 2024 | Allow | 41 | 3 | 1 | No | No |
| 17064317 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2020 | December 2024 | Abandon | 50 | 1 | 2 | No | No |
| 17020558 | Dimeric Quinacrine Derivatives As Autophagy Inhibitors For Cancer Therapy | September 2020 | February 2025 | Abandon | 53 | 5 | 1 | No | No |
| 16991196 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | August 2020 | March 2025 | Allow | 55 | 7 | 1 | No | No |
| 16967214 | GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF | August 2020 | August 2024 | Allow | 49 | 3 | 0 | No | No |
| 16690662 | PULLULAN BASED VINPOCETINE TABLETS, LYOPLANT-TABS, AS A BUCCAL SOLID DOSAGE FORM | November 2019 | April 2020 | Allow | 5 | 1 | 0 | No | No |
| 16408701 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE | May 2019 | March 2020 | Allow | 10 | 1 | 0 | No | No |
| 16385606 | METHODS AND COMPOSITIONS FOR INHIBITION OF BROMODOMAIN-CONTAINING PROTEINS | April 2019 | March 2020 | Allow | 11 | 1 | 0 | No | No |
| 16359068 | COMPOSITIONS COMPRISING TRITERPENOIDS | March 2019 | October 2019 | Allow | 7 | 1 | 0 | No | No |
| 16155982 | CONDITIONING AGENT AND CONDITIONING COMPOSITION | October 2018 | August 2019 | Allow | 10 | 1 | 1 | No | No |
| 16127932 | POTENT CYTOTOXIC AGENT AGAINST HUMAN HEPATOCELLULAR CARCINOMA CELL LINE BASED ON 2-ARYL HYDRAZONOPROPANAL PHARMACOPHORE | September 2018 | January 2019 | Allow | 4 | 1 | 0 | No | No |
| 16062320 | PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE | June 2018 | April 2019 | Allow | 10 | 1 | 0 | No | No |
| 15916140 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | March 2018 | January 2019 | Allow | 10 | 1 | 0 | No | No |
| 15902316 | METHODS FOR TREATING CNS LESIONS | February 2018 | March 2019 | Allow | 13 | 1 | 0 | Yes | No |
| 15754133 | COMPOSITIONS AND METHODS FOR SELECTIVELY INHIBITING INTESTINAL CARBOXYLESTERASE 2 ENZYME ACTIVITY | February 2018 | February 2019 | Allow | 12 | 1 | 0 | No | No |
| 15873540 | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE | January 2018 | February 2019 | Allow | 13 | 1 | 0 | No | No |
| 15571240 | INDOLINYL-SULFONAMIDE INHIBITORS OF TANKYRASE AND METHODS OF USE THEREOF | November 2017 | May 2019 | Allow | 18 | 1 | 0 | No | No |
| 15565317 | USE OF FACTOR XA INHIBITORS FOR REGULATING GLYCEMIA | October 2017 | October 2018 | Allow | 12 | 1 | 0 | No | No |
| 15722194 | 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators | October 2017 | April 2018 | Allow | 7 | 1 | 0 | No | No |
| 15561805 | METHODS FOR TREATMENT OF RETINAL DISEASE BY PHOTORECEPTOR GENE EXPRESSION MODULATION | September 2017 | March 2019 | Allow | 17 | 1 | 0 | No | No |
| 15553882 | COMBINATION OF A RETINOID AND A DIOL AND POLYUNSATURATED FATTY ACID ESTER | August 2017 | October 2018 | Allow | 14 | 1 | 0 | No | No |
| 15552743 | A SYNERGISTIC INSECTICIDAL COMPOSITION | August 2017 | October 2019 | Allow | 26 | 2 | 1 | No | No |
| 15546279 | PARENTERAL AND TOPICAL COMPOSITIONS FOR PAIN | July 2017 | July 2018 | Allow | 12 | 1 | 0 | Yes | No |
| 15634768 | Methods and Compositions for Inhibition of Bromodomain-Containing Proteins | June 2017 | December 2018 | Allow | 18 | 2 | 0 | No | No |
| 14902783 | BORONIC ACID DERIVATIVES OF RESVERATROL FOR ACTIVATING DEACETYLASE ENZYMES | January 2016 | July 2019 | Allow | 42 | 3 | 1 | No | Yes |
| 12250238 | ESTERS OF FLORFENICOL | October 2008 | May 2009 | Allow | 7 | 1 | 0 | No | No |
| 11827481 | LEVALBUTEROL HYDROCHLORIDE POLYMORPH A | July 2007 | September 2008 | Allow | 14 | 1 | 0 | No | No |
| 11810409 | CYCLOALKYL SUBSTITUTED POLYAMINES FOR CANCER THERAPY AND METHODS OF SYNTHESIS THEREFOR | June 2007 | April 2008 | Allow | 11 | 1 | 0 | No | No |
| 11787962 | PRODUCTION OF CHIRALLY PURE AMINO ALCOHOL INTERMEDIATES, DERIVATIVES THEREOF, AND USES THEREOF | April 2007 | May 2009 | Allow | 25 | 1 | 0 | No | No |
| 11694023 | BIFUNCTIONAL ENERGY-REVERSIBLE ACYL-COMPOSITIONS | March 2007 | August 2008 | Allow | 16 | 1 | 1 | No | No |
| 11708283 | PROCESS FOR PREPARATION OF PHENETHYLAMINE DERIVATIVES | February 2007 | March 2009 | Allow | 25 | 3 | 0 | No | No |
| 11700073 | FENICOL COMPOUNDS AND METHODS SYNTHESIZING 2-TRIFLUOROACETAMIDO-3-SUBSTITUTED PROPIOPHENONE COMPOUNDS | January 2007 | December 2008 | Allow | 22 | 2 | 0 | No | No |
| 11657749 | 3(4),7(8)-BIS(AMINOMETHYL)BICYCLO[4.3.0]NONANE AND A PROCESS FOR ITS PREPARATION | January 2007 | November 2007 | Allow | 9 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAVIS, BRIAN J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 57.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DAVIS, BRIAN J works in Art Unit 1614 and has examined 251 patent applications in our dataset. With an allowance rate of 91.6%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 18 months.
Examiner DAVIS, BRIAN J's allowance rate of 91.6% places them in the 76% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by DAVIS, BRIAN J receive 1.24 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by DAVIS, BRIAN J is 18 months. This places the examiner in the 93% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +9.4% benefit to allowance rate for applications examined by DAVIS, BRIAN J. This interview benefit is in the 44% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 40.7% of applications are subsequently allowed. This success rate is in the 91% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 73.2% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 13.5% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.1% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.